Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
With this approval, RYALTRIS® is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population.
Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 2307, up 0.08% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.45% on the day, quoting at 24160.1. The Sensex is at 77455.4, up 0.52%. Glenmark Pharmaceuticals Ltd has risen around 6.97% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has risen around 7.92% in last one month and is currently quoting at 25907.1, up 0.64% on the day. The volume in the stock stood at 2.35 lakh shares today, compared to the daily average of 5.85 lakh shares in last one month.
The benchmark July futures contract for the stock is quoting at Rs 2315.7, up 0.36% on the day. Glenmark Pharmaceuticals Ltd is up 4.64% in last one year as compared to a 4.17% drop in NIFTY and a 15.39% drop in the Nifty Pharma index.
The PE of the stock is 40.66 based on TTM earnings ending March 26.
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Glenmark's Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa®2 IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253].
According to IQVIA® sales data for the 12-month period ending May 2026, the Zyprexa® IntraMuscular Injection market achieved annual sales of approximately $25.4 million.
According to IQVIA sales data for the 12-month period ended May 2026, the reference product recorded annual sales of approximately $25.4 million in the US.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectable portfolio and strengthening our presence within the institutional channel. It reflects our continued commitment to expanding access to quality and affordable treatment options to meet the evolving needs of patients and healthcare providers.”
Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.
The company reported a 6,381.9% increase in consolidated net profit to Rs 301.41 crore on a 16.8% increase in revenue from operations to Rs 3,760.28 crore in Q4 FY26, compared with Q4 FY25.
Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 2260.5, up 2.24% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.68% on the day, quoting at 24436.8. The Sensex is at 78319.33, up 0.71%. Glenmark Pharmaceuticals Ltd has gained around 3.86% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 6.64% in last one month and is currently quoting at 25745.15, up 0.02% on the day. The volume in the stock stood at 3.7 lakh shares today, compared to the daily average of 5.9 lakh shares in last one month.
The benchmark July futures contract for the stock is quoting at Rs 2272.5, up 2.24% on the day. Glenmark Pharmaceuticals Ltd is up 21.53% in last one year as compared to a 4.02% slide in NIFTY and a 15.14% slide in the Nifty Pharma index.
The PE of the stock is 38.97 based on TTM earnings ending March 26.
Glenmark Specialty S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals (Glenmark) announced the advancement of its multi-country Phase 3 clinical trial for Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody drug conjugate (ADC), for patients with platinum-resistant ovarian cancer (PROC).
India will serve as the first country in Glenmark's licensed markets to initiate patient enrollment for the Phase 3 clinical trial, following the approval of Drugs Controller General of India (DCGI). Glenmark also plans to enroll patients in Australia and South Korea, subject to regulatory approvals.
The study is aligned with Jiangsu Hengrui Pharmaceuticals Co.'s ongoing parent Phase 3 trial in China. Glenmark aims to generate clinically relevant data across broader and more diverse patient populations, supporting the development of Trastuzumab rezetecan across Glenmark's licensed markets. The randomized, controlled, multi-centre, Phase 3 trial is designed to evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab rezetecan in patients with HER2-expressing platinum-resistant ovarian cancer, a difficult-to-treat disease where treatment options remain limited, and outcomes continue to be poor. Conducting the trial across multiple geographies is expected to support the generation of evidence from diverse patient groups and strengthen the clinical data package for the therapy across Glenmark's licensed markets.
Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single Dose Vial.
Glenmark's Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL), of Provepharm SAS [NDA 204630].
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “The launch of Methylene Blue Injection USP reflects Glenmark's ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. This addition further strengthens our institutional portfolio and reinforces our focus on delivering reliable treatment options across the U.S. market.”
The company said its product is bioequivalent and therapeutically equivalent to ProvayBlue Injection, 50 mg/10 mL (5 mg/mL), the reference listed drug of Provepharm SAS.
Citing IQVIA sales data, Glenmark noted that the ProvayBlue injection market recorded annual sales of about $19 million for the 12-month period ended April 2026.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “the launch of Methylene Blue Injection USP reflects Glenmark’s ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. This addition further strengthens our institutional portfolio and reinforces our focus on delivering reliable treatment options across the U.S. market.”
The counter fell 1.31% to Rs 2,128.50 on the BSE.